Stay tuned: Bio­gen’s num­bers are great — it’s their wor­ri­some fu­ture that leaves an­a­lysts skit­tish

Bio­gen came out with an up­beat as­sess­ment of their Q2 num­bers to­day, dis­count­ing the ar­rival of a key ri­val for its block­buster Spin­raza fran­chise. But the top ex­ecs re­main grim­ly de­ter­mined to not say much any­thing new about the sore points that have dragged down its stock, in­clud­ing the fu­ture of its big in­vest­ment in Alzheimer’s or how it plans to in­vest the con­sid­er­able cash that the big biotech con­tin­ues to reap.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER